ICER says Pfizer's Paxlovid, Merck's molnupiravir both cost effective, but their benefits are far from equal

Weighing three outpatient treatments for COVID-19, the drug cost watchdog Institute for Clinical and Economic Review (ICER) has determined that Pfizer’s Paxlovid, Merck and Ridgeback Biotherapeutics’ molnupiravir and generic fluvoxamine all carry reasonable prices—but that’s not to say they are equal.